Delayed trial readouts

Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.

Summary

2,453 date moves: 1,669 later and 784 earlier. The median move later is 246 days.

Date moves

SeenDrugStudyPhaseOld dateNew dateMove
2026-11-20aldesleukinNCT01704716High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Phase 32021-09-302025-01-30+1218 days
2026-11-20Gemcitabine, SintilimabNCT05979818Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung CancerPhase 1/22025-08-312028-10-31+1157 days
2026-11-20Capecitabine, Gemcitabine, Eribulin mesylateNCT06143553Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerPhase 32025-122027-12-31+760 days
2026-11-20Dexamethasone, Ofatumumab, Rituximab, Blinatumomab, MethotrexateNCT02877303Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaPhase 22026-11-012028-11-01+731 days
2026-11-20MethotrexateNCT06252870Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft TransplantationPhase 22027-10-182029-10-18+731 days
2026-11-20Bortezomib, AbataceptNCT05289167Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)Phase 1/22026-082027-11+457 days
2026-11-20Disitamab VedotinNCT06660511Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination With Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.Phase 12025-09-012026-12-01+456 days
2026-11-20Semaglutide (Ozempic)NCT06387199Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous SemaglutidePhase 2/32027-012027-12+334 days
2026-11-20AtezolizumabNCT05498896Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBCPhase 22026-08-312027-05-31+273 days
2026-11-20Elacestrant, AbemaciclibNCT05386108Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerPhase 1/22026-122027-08+243 days
2026-11-20LetrozoleNCT04111978MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)Phase 32027-07-012028-02-01+215 days
2026-11-20BlinatumomabNCT03595917ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CMLPhase 12026-11-012027-06-01+212 days
2026-11-20Capivasertib, OsimertinibNCT07486648Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibPhase 1/22028-10-152029-05-15+212 days
2026-11-20SapanisertibNCT06385496Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Phase 22026-12-312027-06-30+181 days
2026-11-20SapanisertibNCT06390865Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Phase 22026-12-312027-06-30+181 days
2026-11-20Axitinib intravitreal implant (OTX-TKI)NCT05695417Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic RetinopathyPhase 12024-012024-05-28+148 days
2026-11-20ontunisertibNCT07672574Human Mass Balance Study of [14C] Ontunisertib in Healthy VolunteersPhase 12026-09-262027-01-31+127 days
2026-11-20Rifaximin SSDNCT05071716Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisPhase 32025-092025-12-23+113 days
2026-11-20Zoledronic acidNCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of BonePhase 32027-012027-04+90 days
2026-11-20Oxycodone (Xtampza ER)NCT03823534Post-Op Pain Control for Prophylactic Intramedullary Nailing.Phase 32026-12-312027-03-31+90 days
2026-11-20GoserelinNCT07777263ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)Phase 32035-102035-12+61 days
2026-11-20SHR-1139NCT07078695A Trial of SHR-1139 in Healthy VolunteersPhase 12026-09-302026-11-09+40 days
2026-11-20Semaglutide (Wegovy)NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 YearsPhase 32031-022031-03+28 days
2026-11-19AnakinraNCT05805930Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in ChildrenPhase 32025-06-012027-10-01+852 days
2026-11-19SilevertinibNCT05256290Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsPhase 1/22025-11-032028-03+849 days
2026-11-19Trastuzumab Deruxtecan, AfatinibNCT06085755Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerPhase 1/22025-122027-12-01+730 days
2026-11-19ColesevelamNCT06197763Impact of Therapy Using Colesevelam Treatment Reducing Bile Acids in Patients With Fontan Circulation.Phase 1/22025-11-012027-07-30+636 days
2026-11-19FulvestrantNCT05826964Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerPhase 22026-07-312027-11-30+487 days
2026-11-19Niraparib, BevacizumabNCT04734665Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP InhibitorPhase 22023-03-312024-07-11+468 days
2026-11-19AlmonertinibNCT06463171Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerPhase 22026-062027-08-01+426 days
2026-11-19Dexamethasone, DocetaxelNCT04947189Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast CancerPhase 1/22026-072027-07-01+365 days
2026-11-19Azacitidine, VenetoclaxNCT07163793Pilot Study of Reduced Venetoclax ExposurePhase 22026-102027-10+365 days
2026-11-19Ruxolitinib (Jakafi), AbataceptNCT07238712Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorPhase 22026-12-102027-12-10+365 days
2026-11-19TislelizumabNCT07389187Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Phase 12026-122027-12+365 days
2026-11-19SelpercatinibNCT05668962Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCPhase 22025-03-012026-01-13+318 days
2026-11-19teduglutide (Gattex)NCT07400783TED_ORG: Study on Short Bowel SyndromePhase na2026-032027-01+306 days
2026-11-19Tamoxifen (Soltamox)NCT05156892Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian CancerPhase 12026-01-012026-11-01+304 days
2026-11-19Sacituzumab GovitecanNCT04559230Sacituzumab Govitecan in Recurrent GlioblastomaPhase 22027-022027-08+181 days
2026-11-19PovetaciceptNCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Phase 2/32028-12-292029-06-27+180 days
2026-11-19Psilocybin (COMP360)NCT07373535Understanding Music and Mindfulness Preferences in Psilocybin-Assisted PsychotherapyPhase 22028-072028-12+153 days
2026-11-19TicagrelorNCT06691191Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 InhibitorsPhase 42026-08-312026-12-31+122 days
2026-11-19AND017NCT07494409A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaPhase 32026-10-302027-02-20+113 days
2026-11-19AND017NCT07487727A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Phase 32026-12-012027-03-01+90 days
2026-11-19tocilizumabNCT05207670A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell MalignanciesPhase 22027-07-312027-10-01+62 days
2026-11-19efsubaglutide alfaNCT07114419The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)Phase 22026-06-012026-07-06+35 days
2026-11-19Dexamethasone, Cevostamab, Elotuzumab, Pomalidomide, Daratumumab, CarfilzomibNCT07555938Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPhase 32028-10-312028-11-30+30 days
2026-11-19Depemokimab, MepolizumabNCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Phase 32026-09-292026-10-06+7 days
2026-11-18Sintilimab, BevacizumabNCT05363722Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCCPhase 12023-042029-01+2102 days
2026-11-18Patritumab DeruxtecanNCT06172478A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid TumorsPhase 22027-09-012030-11-19+1175 days
2026-11-18MitapivatNCT05935202Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte MembranopathiesPhase 22025-07-152028-09-30+1173 days
2026-11-18ObudanersenNCT05127226HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromePhase 1/22029-032032-03+1096 days
2026-11-18Tobevibart (VIR-3434)NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionPhase 22026-112029-03+851 days
2026-11-18Futibatinib (Lytgobi), Amivantamab, AtezolizumabNCT03767075A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)Phase 22025-052027-05+730 days
2026-11-18IvabradineNCT04111133Ivabradine in Cirrhotic CardiomyopathyPhase na2024-102026-10-01+730 days
2026-11-18Gemcitabine, S-1, TislelizumabNCT06903273Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk CholangiocarcinomaPhase 22028-07-012030-07-01+730 days
2026-11-18tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Tenofovir disoproxil fumarate (Viread), Doravirine, BictegravirNCT07075146DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityPhase 32026-06-052027-12-05+548 days
2026-11-18LetrozoleNCT06913075FET in AdenomyosisPhase na2026-07-152027-09-15+427 days
2026-11-18Dexamethasone, IxazomibNCT03618537Ixazomib Maintenance Study in Patients With AL AmyloidosisPhase 22026-082027-08+365 days
2026-11-18BinimetinibNCT06159478Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic CancerPhase 22027-02-282028-02-28+365 days
2026-11-18Rifaximin (Xifaxan)NCT06538077BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HEPhase 42026-082027-08+365 days
2026-11-18Cannabidiol (Epidiolex)NCT06014424Cannabidiol Medication Intervention TrialPhase 22026-12-292027-12+337 days
2026-11-18IAM1363NCT06253871A Phase 1/2 Study of IAM1363 in HER2 CancersPhase 1/22027-122028-10+305 days
2026-11-18Diroximel fumarateNCT06913920Mechanical Modalities Combined With Standard Therapy Versus Standard Therapy Alone for Edema and Pain Management After Distal Radius Fracture FixationPhase na2026-01-152026-10-28+286 days
2026-11-18Methotrexate, etanerceptNCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiSPhase 32025-02-282025-10-31+245 days
2026-11-18Diroximel fumarateNCT06913894Supervised vs. Home-Based vs. No Therapy for Uncomplicated Distal Radius Fracture in Younger AdultsPhase na2026-04-212026-10-27+189 days
2026-11-18faricimabNCT06790784Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDRPhase 32031-082032-02+184 days
2026-11-18Insulin LisproNCT06945406A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 DiabetesPhase 12027-032027-07+122 days
2026-11-18viloxazineNCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Phase 32026-092026-12+91 days
2026-11-18Ranibizumab, Surabgene lomparvovecNCT04514653RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)Phase 22026-082026-10-13+73 days
2026-11-18TemozolomideNCT07935889Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 TrialPhase 32035-11-022035-11-30+28 days
2026-11-18RabeprazoleNCT07797478A Study of RO7890597 in Healthy Adult VolunteersPhase 12027-06-082027-06-15+7 days
2026-11-17Duloxetine, Pregabalin, GabapentinNCT07593313Treatment of Post-Stroke Central PainPhase na2026-08-012029-08-01+1096 days
2026-11-17AvelumabNCT03774901Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile CarcinomaPhase 22024-09-222026-10-30+768 days
2026-11-17zanubrutinib, RituximabNCT05914662Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMPhase 22025-03-152026-11-15+610 days
2026-11-17zasocitinibNCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisPhase 32033-01-242034-07-03+525 days
2026-11-17Bevacizumab, Nab-paclitaxel, Relacorilant (Lifyorli)NCT06906341Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersPhase 22026-082027-12+487 days
2026-11-17TSN1611NCT06385925A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D MutationPhase 1/22026-10-302027-10-30+365 days
2026-11-17PembrolizumabNCT03829254A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and LymphomaPhase 1/22026-082027-07+334 days
2026-11-17EmpagliflozinNCT07472920Empagliflozin Adjunctive Therapy in Bipolar DepressionPhase na2026-092027-08+334 days
2026-11-17dupilumabNCT05268107Ethnic Differences in Mechanisms of Action of DupilumabPhase 42026-122027-07+212 days
2026-11-17RituximabNCT05600686Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaPhase 22026-10-012027-05-01+212 days
2026-11-17Corteria COR-1167NCT06815471CRF2 Agonist for the Treatment of Worsening Heart FailurePhase 22026-122027-07+212 days
2026-11-17Nab-paclitaxel, GemcitabineNCT05064618Investigator-initiated Clinical Trial of MIKE-1Phase 1/22025-04-302025-10-02+155 days
2026-11-17Axatilimab, PembrolizumabNCT07015853ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationPhase 22033-072033-12+153 days
2026-11-17DurvalumabNCT03768570Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder CancerPhase 22026-10-312027-03-31+151 days
2026-11-17Iparomlimab and tuvonralimabNCT07613567QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical CancerPhase 32032-08-312032-12-31+122 days
2026-11-17HRG2010NCT06596876A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor FluctuationsPhase 32025-10-092026-01-29+112 days
2026-11-17PembrolizumabNCT07732634Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck CancerPhase 22029-082029-11+92 days
2026-11-17DostarlimabNCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerPhase 32029-12-122030-03-13+91 days
2026-11-17Purinostat MesylateNCT07809217Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy ParticipantsPhase 12026-10-312026-12-15+45 days
2026-11-17VT-5006NCT07310264Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's DiseasePhase 12026-09-282026-11-10+43 days
2026-11-14Ceralasertib, DurvalumabNCT03780608A Study of AZD6738 in Combination With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemotherapy-Refractory Gastric Cancer; Cohort B: Anti-PD(L)Phase 22022-12-012027-12-01+1826 days
2026-11-14BI 3000202NCT06878365A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 InterferonopathiesPhase 12026-12-062029-12-10+1100 days
2026-11-14Rosuvastatin, LaroprovstatNCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaPhase 2/32025-07-032027-02-22+599 days
2026-11-14NabiximolsNCT05503147Sativex® and Gentamicin for Optimized Pharmagological Treatment in Older Patients (CanPan)Phase 12023-08-012025-01-15+533 days
2026-11-14OsimertinibNCT05748093Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With CobicistatPhase 42026-06-012027-07-01+395 days
2026-11-14Omega-3-acid ethyl esters (Lovaza)NCT02178410VITAL Rhythm StudyPhase 32026-102027-10+365 days
2026-11-14obefazimodNCT07453784Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet FormulationPhase 12026-092027-04+212 days
2026-11-14aldesleukinNCT06107894TIL Therapy for Patients With Advanced Solid TumorsPhase 12025-092026-02-28+180 days
2026-11-14upadacitinibNCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyPhase 32028-032028-08+153 days
2026-11-14Gemcitabine, DurvalumabNCT07332351Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialPhase 22027-01-012027-06-01+151 days
2026-11-14Trastuzumab Emtansine, InavolisibNCT05894239A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 32026-12-312027-05-03+123 days
2026-11-14ADSTEMNCT07377838Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic DermatitisPhase 32029-062029-09+92 days
2026-11-14SuzetrigineNCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic SurgeryPhase 32026-12-312027-03-31+90 days
2026-11-14AZD4954NCT07812077A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954Phase 12026-12-172027-03-17+90 days
2026-11-14survodutideNCT07407348A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyPhase 12027-01-262027-04-09+73 days
2026-11-14OmalizumabNCT06618963Effect of Omalizumab in the Skin of Food Allergy PatientsPhase 42026-092026-11-03+63 days
2026-11-14setmelanotideNCT06772597A Study of Setmelanotide in Patients With Prader-Willi SyndromePhase 22026-10-312026-11-03+3 days
2026-11-14BenralizumabNCT03953300Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsPhase 42026-10-192026-10-20+1 day
2026-11-13NivolumabNCT04159818Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsPhase 22022-12-152030-12-15+2922 days
2026-11-13AxitinibNCT06485908Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and EpendymomaPhase 1/22026-042032-02+2132 days
2026-11-13tenofovir alafenamide (Vemlidy)NCT04939441Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)Phase 42024-05-012027-12-31+1339 days
2026-11-13SerplulimabNCT05311189Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric CancerPhase 22023-12-312026-12-31+1096 days
2026-11-13MavacamtenNCT07807384Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyPhase 42026-092029-09+1096 days
2026-11-13LBL-034NCT06049290A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaPhase 1/22026-10-202029-09-20+1066 days
2026-11-13MethylprednisoloneNCT05139849VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical TrialPhase 32027-01-312029-01-31+731 days
2026-11-13AtezolizumabNCT05681039Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Phase 22026-11-012028-11-01+731 days
2026-11-13Sargramostim, Ipilimumab, PembrolizumabNCT04739618Metastatic Solid Cancer Clinical TrialPhase 22024-122026-11-10+709 days
2026-11-13IRX4204NCT06723171Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque PsoriasisPhase 22026-032027-12+640 days
2026-11-13RituximabNCT06952413Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)Phase 22026-09-302028-05-31+609 days
2026-11-13AK146D1NCT06929663A Study of AK146D1 as Monotherapy and in Combination With AK104 or AK112, in the Treatment of Advanced Solid TumorsPhase 12026-11-052028-06-30+603 days
2026-11-13pemetrexed, CadonilimabNCT06762080Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal MetastasisPhase 1/22026-10-302027-12-30+426 days
2026-11-13infliximabNCT06758024PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel DiseasePhase na2026-012027-03+424 days
2026-11-13AnakinraNCT03587701Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear DiseasePhase 22026-12-312027-12-31+365 days
2026-11-13EpcoritamabNCT06510361A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront TherapyPhase 22026-05-012027-05-01+365 days
2026-11-13Decitabine/cedazuridine (Inqovi)NCT05178693Lutathera and ASTX727 in Neuroendocrine TumoursPhase 12026-06-302027-05-30+334 days
2026-11-13CetuximabNCT06447987Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic LeukemiaPhase 12026-12-052027-10-29+328 days
2026-11-13LAE102NCT06493084Evaluate LAE102 in Healthy and Overweight/Obese SubjectsPhase 12026-09-302027-06-30+273 days
2026-11-13SotorasibNCT06659341A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C MutationPhase 12027-04-262027-11-30+218 days
2026-11-13TislelizumabNCT06420440Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelPhase 22026-05-312026-12-31+214 days
2026-11-13NiraparibNCT05694715Combination Therapy in Cancers With Mutations in DNA Repair GenesPhase 12028-01-312028-08-31+213 days
2026-11-13Lithium salicylate/L-proline (AL001)NCT07540338A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderPhase 1/22026-122027-07+212 days
2026-11-13Diroximel fumarateNCT06913933Static vs. Dynamic Progressive Splinting for Persistent Wrist Stiffness After DRFPhase na2026-04-172026-10-08+174 days
2026-11-13Dexamethasone, Lenalidomide, Daratumumab, CarfilzomibNCT03606577An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsPhase 22022-02-082022-07-18+160 days
2026-11-13XTR003NCT07443696PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic CardiomyopathyPhase 22026-082026-12-31+152 days
2026-11-13Emtricitabine (Emtriva), tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Dolutegravir, VH4524184NCT07202546A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)Phase 22027-06-112027-10-28+139 days
2026-11-13Docetaxel, OSE2101NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPhase 32027-12-152028-05-01+138 days
2026-11-13BI 3000202NCT07774325A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the BloodPhase 12026-10-062027-02-21+138 days
2026-11-13EsketamineNCT07753772Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral ReconstructionPhase 42029-072029-11+123 days
2026-11-13IfebemtinibNCT06014528IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian CancerPhase 22026-12-242027-03-24+90 days
2026-11-13SaruparibNCT06713369AZD5305 hADME in Patients With Advanced Solid MalignanciesPhase 12026-10-022026-12-31+90 days
2026-11-13VadadustatNCT06520826Vafseo Outcomes In-Center ExperiencePhase 32026-06-302026-09-10+72 days
2026-11-13AcoramidisNCT07298044A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to AcoramidisPhase 42027-07-152027-09-17+64 days
2026-11-13Naloxone (Narcan)NCT05027919Assessing a Clinically-meaningful Opioid Withdrawal PhenotypePhase 22026-11-302027-01-30+61 days
2026-11-13GabapentinNCT06565546CYP2D6 Genotype-guided Management of Opioid Analgesics in Patients Undergoing Elective Ventral Hernia RepairsPhase na2026-09-012026-10-31+60 days
2026-11-13EverolimusNCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPhase 32026-12-302027-02-26+58 days
2026-11-13tenofovir alafenamide (Vemlidy), Tenofovir disoproxil fumarate (Viread)NCT02932150Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus InfectionPhase 22026-092026-10-27+56 days
2026-11-13MET-233iNCT07022977A Study of MET233 in Individuals With Obesity or OverweightPhase 12026-04-212026-05-28+37 days
2026-11-13tocilizumab, PembrolizumabNCT07889232Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung CancerPhase 1/22029-04-302029-05-31+31 days
2026-11-13GemcitabineNCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAPhase 2/32029-01-012029-01-31+30 days
2026-11-13Odronextamab, RituximabNCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaPhase 32028-02-072028-02-29+22 days
2026-11-13GSK4527363NCT06576271A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsPhase 12028-01-112028-02-01+21 days
2026-11-13Ruxolitinib (Opzelura)NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Phase 32026-10-092026-10-29+20 days
2026-11-13AlimatravirNCT07661108A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)Phase 12026-10-092026-10-28+19 days
2026-11-13Sevabertinib, metforminNCT07753252Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the BodyPhase 12026-10-062026-10-08+2 days
2026-11-11pemetrexed, CemiplimabNCT07720167Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerPhase 22029-11-012035-08-01+2099 days
2026-11-11MethotrexateNCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisPhase 2/32026-072031-11+1949 days
2026-11-11Vemurafenib, Pertuzumab, Dabrafenib, Pemigatinib, Entrectinib, Cobimetinib, Abemaciclib, Regorafenib, Tepotinib, Alectinib, Trametinib, AtezolizumabNCT05159245The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsPhase 22026-11-252031-11-25+1826 days
2026-11-11BevacizumabNCT07005570Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer (SPARK)Phase 22027-07-012031-12-31+1644 days
2026-11-11Obinutuzumab, GemcitabineNCT06806033Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLPhase 22027-01-312029-07-31+912 days
2026-11-11MepolizumabNCT05923047Mepolizumab and In-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Three Arm Study.Phase 42024-09-012027-01-01+852 days
2026-11-11Rituximab, PirtobrutinibNCT06263491Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsPhase 22026-11-012028-11-01+731 days
2026-11-11BrigatinibNCT03707938Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerPhase 12026-01-282028-01-28+730 days
2026-11-11RilvegostomigNCT04995523A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCPhase 1/22026-08-282028-06-01+643 days
2026-11-11lutikizumab, risankizumabNCT06865105Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPhase 22027-122029-08+609 days
2026-11-11SintilimabNCT06054906Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric CancerPhase 22025-06-302026-12-30+548 days
2026-11-11Colchicine (cardiovascular)NCT06217120Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection FractionPhase 22025-10-012027-04+547 days
2026-11-11InclisiranNCT06865885LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL LoweringPhase 42026-12-302028-06-01+519 days
2026-11-11Capecitabine, GemcitabineNCT06434493Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar CholangiocarcinomaPhase na2028-06-012029-11-01+518 days
2026-11-11Nab-paclitaxel, GemcitabineNCT03492671Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic CancerPhase 22026-092027-10+395 days
2026-11-11metforminNCT07001878Cannabis Potency Effects on Brain White Matter in Early Phase PsychosisPhase 42026-08-312027-09-30+395 days
2026-11-11MepolizumabNCT06041386REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive StudyPhase 42025-01-312026-02-12+377 days
2026-11-11Trastuzumab Deruxtecan, OlaparibNCT06525298EIS-12656 as Single Agent and in Combination in Patients With Specified Solid TumorsPhase 1/22027-092028-09+366 days
2026-11-11CemiplimabNCT05574101A Study of Radiation Therapy and Cemiplimab for People With Skin CancerPhase 22026-10-062027-10-06+365 days
2026-11-11Fianlimab, CemiplimabNCT06848088A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma TreatmentPhase 22029-10-102030-10-09+364 days
2026-11-11EsketamineNCT05450432Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With DepressionPhase 42026-06-012027-05-01+334 days
2026-11-11TislelizumabNCT07557914Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesPhase 22029-022029-12+303 days
2026-11-11Fianlimab, Cemiplimab, PembrolizumabNCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPhase 32026-07-272027-01-15+172 days
2026-11-11BevacizumabNCT06106308Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationPhase 22026-112027-04-16+166 days
2026-11-11GemcitabineNCT06454383Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic CancerPhase 12026-11-132027-03-23+130 days
2026-11-11BelumosudilNCT07726914Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsPhase 12026-09-282027-01-26+120 days
2026-11-11Rosuvastatin, elecoglipronNCT07534592A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsPhase 12026-10-012027-01-25+116 days
2026-11-11tocilizumabNCT07254637Tocilizumab in Chronic Inflammatory CPPD DiseasePhase 22026-102026-11+31 days
2026-11-11BofanglutideNCT07141030Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionPhase 12025-10-092025-10-20+11 days
2026-11-11zenagamtide, Semaglutide (Ozempic)NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPhase 32028-12-122028-12-19+7 days
2026-11-11BofanglutideNCT07355738Bioequivalence Study of GZR18 Injection Before and After CMC ChangePhase 12026-05-202026-05-22+2 days
2026-11-10PembrolizumabNCT05394103Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsPhase 1/22025-12-302029-03-31+1187 days
2026-11-10IncobotulinumtoxinA (Xeomin)NCT00909883Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)Phase 32011-092013-11-12+803 days
2026-11-10NivolumabNCT05964101Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell CarcinomaPhase 22025-08-012027-08-01+730 days
2026-11-10AmbroxolNCT06193421High-Dose Ambroxol in GBA1-Related ParkinsonPhase 1/22025-02-272026-03-30+396 days
2026-11-10QuemliclustatNCT05688215Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaPhase 1/22026-12-012027-12-31+395 days
2026-11-10Tremelimumab, DurvalumabNCT05701488SIRT With Tremelimumab and Durvalumab for Resectable HCCPhase 12026-10-012027-10-01+365 days
2026-11-10Cladribine (MAVENCLAD®), natalizumabNCT04178005Cladribine Tablets After Treatment With Natalizumab (CLADRINA)Phase 42026-08-302027-05-30+273 days
2026-11-10DexamethasoneNCT07607691Ultrasound-Guided PENG Block for Chronic Shoulder PainPhase na2026-10-012027-07-01+273 days
2026-11-10Venetoclax, Ibrutinib, Lenalidomide, ObinutuzumabNCT03223610Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaPhase 1/22026-12-012027-08-12+254 days
2026-11-10Ruxolitinib (Jakafi)NCT07278856Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasPhase 12027-03-312027-12-10+254 days
2026-11-10Idecabtagene vicleucel, MezigdomideNCT06048250Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple MyelomaPhase 12026-09-212027-02-09+141 days
2026-11-10Rituximab, AcalabrutinibNCT04002947Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaPhase 22027-05-312027-10-12+134 days
2026-11-10Sacituzumab Tirumotecan, Pembrolizumab, OsimertinibNCT05816252A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Phase 22026-06-302026-08-31+62 days
2026-11-10Olanzapine (Zyprexa)NCT07581405GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric CancerPhase 22028-092028-11+61 days
2026-11-10aldesleukinNCT05194735Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsPhase 1/22023-08-142023-09-30+47 days
2026-11-10ZiftomenibNCT06930352Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard TherapyPhase 22027-12-312028-01-31+31 days
2026-11-10Sotagliflozin (Inpefa)NCT06433050Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic CardiomyopathyPhase 12027-042027-05+30 days
2026-11-08BosentanNCT02377271ENDOTHELION Study Group: Effect of Bosentan in NAION PatientsPhase 32023-122027-02+1158 days
2026-11-08AndecaliximabNCT07024407A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.Phase 1/22025-122028-12+1096 days
2026-11-08Tarlatamab, DurvalumabNCT06211036Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabPhase 32027-07-052030-04-02+1002 days
2026-11-08Bevacizumab, AtezolizumabNCT06823375SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein ThrombosisPhase 22027-07-312029-03-31+609 days
2026-11-08Lurbinectedin, DurvalumabNCT07459634A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCPhase 22028-01-312029-08-04+551 days
2026-11-08Cannabidiol (Epidiolex)NCT05015439Cannabidiol (CBD) in Adults With ASDPhase 12026-122027-12+365 days
2026-11-08Olanzapine (Zyprexa)NCT06200181Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control TrialPhase 32026-11-012027-11-01+365 days
2026-11-08DexamethasoneNCT04150614BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to OndansetronPhase 42026-072027-03+243 days
2026-11-08metforminNCT06948825Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational DiabetesPhase 22026-112027-05+181 days
2026-11-08DexamethasoneNCT06304324Dexmedetomidine vs Dexamethasone in Popliteal Nerve BlockPhase 42025-03-312025-07-08+99 days
2026-11-08PertuzumabNCT02320435A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialPhase 32026-12-312027-03-28+87 days
2026-11-08BevacizumabNCT07851025Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian CancerPhase 32030-06-182030-06-28+10 days
2026-11-07LumipodlinNCT04964375A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid TumorPhase 12022-10-232027-07-30+1741 days
2026-11-07infliximab-dyyb (Inflectra), Methotrexate, infliximabNCT05072782Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)Phase 42023-06-302026-10-15+1203 days
2026-11-07Ferric derisomaltoseNCT05971732The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)Phase 42024-08-012027-08-01+1095 days
2026-11-07Ferric derisomaltoseNCT05991128The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of LifePhase 42024-08-012027-08-01+1095 days
2026-11-07Ruxolitinib (Jakafi)NCT05622318De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) ProphylaxisPhase 22026-072028-07-08+738 days
2026-11-07Ipilimumab, Nivolumab, CiforadenantNCT05501054Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Phase 1/22026-11-012028-11-01+731 days
2026-11-07TNX-1500NCT07204080(TNX-1500) in Kidney Transplant RecipientsPhase 22029-09-012031-09-01+730 days
2026-11-07PembrolizumabNCT04875585Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLCPhase 22023-122025-11-17+717 days
2026-11-07tocilizumab, AbataceptNCT03227419Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate RespondersPhase 42024-092026-01-29+515 days
2026-11-07R289NCT05308264Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)Phase 1/22026-082027-12+487 days
2026-11-07DexamethasoneNCT06233604Dexamethasone vs. Dexmedetomidine for ESPB in Pain Management After Hip ArthroplastyPhase 42025-03-302026-06-30+457 days
2026-11-07YKST02NCT07695740Study of YKST02 in Adults With Relapsed or Refractory Multiple MyelomaPhase 22029-092030-12+456 days
2026-11-07AnakinraNCT04148430A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell TherapyPhase 22026-102027-10+365 days
2026-11-07NaltrexoneNCT06306157Low Dose Naltrexone Therapy for Complex Regional Pain SyndromePhase 42026-082027-08+365 days
2026-11-07Psilocybin (COMP360), PimavanserinNCT06592833Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderPhase 22028-03-012029-03+365 days
2026-11-07metforminNCT06463743Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)Phase 22027-01-012027-12-01+334 days
2026-11-07IvonescimabNCT06793332BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCPhase 22026-01-312026-12-31+334 days
2026-11-07Famitinib, CamrelizumabNCT05999149A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)Phase 32025-08-302026-05-30+273 days
2026-11-07MRT-2359NCT05546268Study of Oral MRT-2359 in Selected Cancer PatientsPhase 1/22026-052026-12+214 days
2026-11-07DostarlimabNCT05201547Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First LinePhase 32026-042026-10-01+183 days
2026-11-07FampridineNCT06136728Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple SclerosisPhase 32026-122027-05+151 days
2026-11-07vedolizumab, ustekinumabNCT06788340MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel DiseasePhase 42027-08-302027-12-30+122 days
2026-11-07PembrolizumabNCT07783581Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI TrialPhase 22030-04-012030-06-01+61 days
2026-11-07ZiltivekimabNCT06263244Specifying the Anti-inflammatory Effects of ZiltivekimabPhase 32026-09-042026-10-30+56 days
2026-11-07REGN20423NCT07527923First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisPhase 12028-06-232028-08-14+52 days
2026-11-07albuterol (Ventolin), Salbutamol HFA-152aNCT06433921A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 InclusivePhase 12027-02-262027-04-16+49 days
2026-11-07pemetrexed, OsimertinibNCT04769388Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L OsimertinibPhase 22026-01-242026-01-26+2 days
2026-11-07pemetrexed, Ramucirumab, PembrolizumabNCT04332367Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab MaintenancePhase 22026-09-302026-10-01+1 day
2026-11-06baricitinibNCT05056558Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19Phase 32022-042025-07-30+1216 days
2026-11-06AzacitidineNCT07433023tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral PalsyPhase 22029-01-012030-08-31+607 days
2026-11-06VH4524184NCT06310551First Time in Human Study of Long Acting VH4524184 FormulationsPhase 12028-01-212029-05-28+493 days
2026-11-06Tamoxifen (Soltamox)NCT07289035Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.Phase 22026-04-012027-06-30+455 days
2026-11-06RamucirumabNCT04660760Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction CancerPhase 22024-07-312025-09-15+411 days
2026-11-06metforminNCT04194424A Multidisciplinary Weight Loss Program at AUB-MCPhase na2026-09-152027-09-15+365 days
2026-11-06Azacitidine (Onureg)NCT06370000Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-InequalityPhase 42027-01-312028-01-31+365 days
2026-11-06Fianlimab, CemiplimabNCT07224022Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon CancerPhase 22028-12-312029-12-31+365 days
2026-11-06Ferric derisomaltoseNCT06427343The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron DeficiencyPhase 42026-09-302027-08-01+305 days
2026-11-06Ribociclib, Trametinib, Capmatinib, GefitinibNCT03333343Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCPhase 12026-10-052027-07-12+280 days
2026-11-06EnozertinibNCT05315700Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationPhase 1/22026-092027-06+273 days
2026-11-06EmpagliflozinNCT05972564The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial FunctionPhase 1/22026-09-302027-06-30+273 days
2026-11-06IPS101ANCT07371338Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease PatientsPhase 12027-10-312028-06-30+243 days
2026-11-06DexamethasoneNCT07330999Three Variants of the PENG Block With and Without Perineural Adjuvants in Older AdultsPhase na2027-01-012027-08-31+242 days
2026-11-06Bevacizumab, PazopanibNCT01684397Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney CancerPhase 1/22026-08-202027-02-20+184 days
2026-11-06Ropeginterferon alfa-2b (Besremi)NCT07468916Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic LeukemiaPhase 22031-09-302032-01-30+122 days
2026-11-06tovecimigNCT07662031Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal CancerPhase 22030-08-312030-12-31+122 days
2026-11-06DexamethasoneNCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Phase 32028-08-022028-11-30+120 days
2026-11-06Etakafusp alfa, PembrolizumabNCT07300475Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer PatientsPhase 12030-07-312030-09-30+61 days
2026-11-06AfliberceptNCT07798375A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular DegenerationPhase 22028-052028-07+61 days
2026-11-06Aflibercept, Tabirafusp tedromer, Tarcocimab tedromerNCT06556368A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKPhase 32026-082026-09-02+32 days
2026-11-06Furosemide (subcutaneous, SQ Innovation)NCT07018297Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart FailurePhase 32028-08-012028-09-01+31 days
2026-11-06ABBV-295NCT07291232A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With ObesityPhase 12027-032027-04+31 days
2026-11-06DexamethasoneNCT05688475A Rollover Study of CC-122Phase 12026-10-312026-11-30+30 days
2026-11-06maridebart cafraglutide, Semaglutide (Ozempic)NCT07866066Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesPhase 32028-09-042028-09-06+2 days
2026-11-05Gemcitabine, Cemiplimab, Nab-paclitaxelNCT07433673Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)Phase 22028-012032-01+1461 days
2026-11-05Hydroxychloroquine, Dexamethasone, apremilast, tocilizumab, Sarilumab, Anakinra, baricitinibNCT02735707Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPhase 32026-022028-06+851 days
2026-11-05bleximenibNCT04811560A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)Phase 1/22027-02-262028-12-29+672 days
2026-11-05DocetaxelNCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialPhase 22030-03-202031-09-20+549 days
2026-11-05Rinatabart sesutecan (Rina-S), Bevacizumab, PembrolizumabNCT05579366Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/22027-072028-12+519 days
2026-11-05Colchicine (cardiovascular)NCT07654231REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label TrialPhase 22027-12-012029-05-01+517 days
2026-11-05Pirfenidone (Esbriet)NCT07654517Pirfenidone for Idiopathic Subglottic Stenosis: A Pilot Trial of Tolerability and FeasibilityPhase 12027-12-012029-03-31+486 days
2026-11-05Epcoritamab, Rituximab, LenalidomideNCT05201248A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin LymphomaPhase 1/22026-092027-10+395 days
2026-11-05Sintilimab, Nab-paclitaxelNCT05429463Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ)Phase 32025-11-112026-11-30+384 days
2026-11-05PlerixaforNCT02570542Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Phase 22026-102027-10+365 days
2026-11-05Nab-paclitaxel, GemcitabineNCT02921022Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic AdenocarcinomaPhase na2026-102027-10+365 days
2026-11-05NeratinibNCT02932280Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentPhase 1/22026-102027-10+365 days
2026-11-05Pembrolizumab, TarlatamabNCT03319940Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)Phase 12026-12-312027-12-31+365 days
2026-11-05Tamoxifen (Soltamox)NCT03707340A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase InhibitorsPhase 22026-10-142027-10-14+365 days
2026-11-05N-acetylcysteineNCT05081479A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for LymphomaPhase 12026-10-212027-10-21+365 days
2026-11-05Nivolumab, IpilimumabNCT05663775Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)Phase 22026-082027-08+365 days
2026-11-05TemozolomideNCT05664243A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed GlioblastomaPhase 1/22025-122026-12+365 days
2026-11-05Sotagliflozin (Inpefa)NCT07211802CKM For Safe Use of SGLT2i in Type 1 DiabetesPhase 32030-07-312031-07-31+365 days
2026-11-05AtezolizumabNCT06031441A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsPhase 12027-03-032028-03-01+364 days
2026-11-05metforminNCT06452498Preeclampsia Intervention NetherlandsPhase 32028-042029-03-19+352 days
2026-11-05Cabotegravir/rilpivirine (Cabenuva)NCT05418868A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsPhase 12027-06-082028-03-31+297 days
2026-11-05Nab-paclitaxel, Gemcitabine, Tremelimumab, DurvalumabNCT05451043Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)Phase 22026-10-012027-05-01+212 days
2026-11-05PembrolizumabNCT05309421A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic MelanomaPhase 22025-09-302026-04-07+189 days
2026-11-05Nab-paclitaxelNCT06802757Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast CancerPhase 22026-06-302026-12-31+184 days
2026-11-05Rituximab, NivolumabNCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPhase 32026-12-312027-06-30+181 days
2026-11-05Dexamethasone, Lenalidomide, BortezomibNCT05979363A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell LeukemiaPhase 22026-07-012026-12-01+153 days
2026-11-05Monalizumab, Oleclumab, DurvalumabNCT05221840A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerPhase 32026-09-302027-01-08+100 days
2026-11-05ALN-CIDEBNCT06836609A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)Phase 1/22027-05-152027-08-17+94 days
2026-11-05SelinexorNCT05099003A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)Phase 1/22027-06-302027-09-30+92 days
2026-11-05IMV102NCT07802756Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic MalignanciesPhase 12027-09-102027-12-10+91 days
2026-11-05DapagliflozinNCT07295223Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)Phase 32026-082026-10-30+90 days
2026-11-05OmalizumabNCT04045301Omalizumab to Accelerate a Symptom-driven Multi-food OITPhase 22025-122026-02-23+84 days

Showing the newest 300 of 1,669 moves. Each drug page lists every registry date for its own studies.

Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.